Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04408924|
Recruitment Status : Active, not recruiting
First Posted : May 29, 2020
Results First Posted : May 24, 2023
Last Update Posted : May 24, 2023
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Castration-Resistant Prostate Cancer||Drug: Abemaciclib||Phase 2|
Expanded Access : An investigational treatment associated with this study is available outside the clinical trial. More info ...
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||44 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy|
|Actual Study Start Date :||January 20, 2021|
|Actual Primary Completion Date :||April 27, 2022|
|Estimated Study Completion Date :||August 31, 2023|
Experimental: 200 milligram (mg) Abemaciclib Twice Daily
Participants received 200 mg abemaciclib administered orally twice daily on a continuous dosing schedule (28-day cycle) until symptomatic and/or radiographic progression, unacceptable toxicity, or until another discontinuation criterion is met.
Other Name: LY2835219
- Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) [ Time Frame: From Date of First Dose until Objective Progression (Up To 12.8 Months) ]
ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) in soft tissue per response evaluation criteria in solid tumors (RECIST) version 1.1 and do not have concurrent bone progression per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), as assessed by the investigator.
ORR = (participants with confirmed CR and no bone progression) + (participants with confirmed PR and no bone progression) x 100 / all treated participants.
- Radiographic Progression-Free Survival (rPFS) [ Time Frame: From Date of First Dose until Objective Progression or Death from Any Cause (Up To 12.8 Months) ]The rPFS time is measured from the date of first dose to the earliest date of investigator-assessed radiographic progression per RECIST 1.1 for soft tissue and PCWG3 criteria for bone, or death from any cause, whichever occurred first. Participants who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment (if available) or date of first dose if no post initiation (i.e., postbaseline) radiographic assessment is available.
- Overall Survival (OS) [ Time Frame: From Date of First Dose until Date of Death from Any Cause (Estimated Up To 28 Months) ]OS time is measured from the date of first dose to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
- Duration of Response (DoR) [ Time Frame: CR or PR to Disease Progression or Death Due to Any Cause (Estimated Up to 28 Months) ]DoR is measured only for confirmed responders (participants with a confirmed soft tissue best overall response of CR or PR per RECIST 1.1 no concurrent bone progression per PCWG3. It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator-assessed radiographic progression or death from any cause, whichever is earlier.
- Percentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR]) [ Time Frame: From Date of First Dose until Measured Progressive Disease or Death Due to Any Cause (Up To 12.8 Months) ]The DCR is defined as the percentage of participants with confirmed soft tissue best overall response of CR, PR, or stable disease (SD) per RECIST 1.1, and do not have concurrent bone disease progression per PCWG3.
- Time to Prostate-Specific Antigen (PSA) Progression [ Time Frame: From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months) ]Time to PSA progression is defined as the time from the date of treatment initiation to the date of first observation of PSA progression. The PSA progression is defined as a greater than or equal to (>=) 25 percentage (%) increase and an absolute increase of >=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.
- Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate) [ Time Frame: From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months) ]The PSA response rate is defined as the percentage of participants with a reduction in PSA level ≥50% from baseline, confirmed with a second assessment conducted at least 3 weeks later.
- Time to Symptomatic Progression [ Time Frame: From Date of First Dose until Symptomatic Progression (Up to 12.8 Months) ]Time to symptomatic progression is defined as the time from first dose to any of the following (whichever occurred earlier): 1) symptomatic skeletal event, defined as symptomatic fracture, surgery, or radiation to bone, or spinal cord compression; 2) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anticancer therapy; and 3) development of clinically significant symptoms due to locoregional tumor progression requiring surgical intervention or radiation therapy. For participants who were not known to have symptomatic progression at the time of data analysis, data were censored on the last date at which no symptomatic progression was indicated.
- Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib [ Time Frame: Cycle (C) 1 Day (D) 1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose ]PK: Cmax,ss of abemaciclib is reported.
- PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib [ Time Frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose ]PK: Cmin,ss of abemaciclib is reported.
- PK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species) [ Time Frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose ]PK: Cmax,ss of abemaciclib metabolites (Total Active Species) is reported.
- PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species) [ Time Frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose ]PK: Cmin,ss of abemaciclib metabolites (Total Active Species) is reported.
- Baseline Ki-67 Expression by Immunohistochemistry (IHC) [ Time Frame: Baseline ]
Percentage of participants with expression of Ki-67 proliferation marker at baseline by immunohistochemistry.
Baseline expression of the Ki-67 proliferation marker was evaluated by IHC utilizing a 20% or higher score to define high Ki-67 expression. The percentage of Ki-67 positive cells was defined by the number of non-apoptotic tumor cells with unequivocal brown nuclear staining (intensities ≥1 using a 0-3 scale) over the total number of non-apoptotic tumor cells. Unit of Measure is percentage of participants with low or high baseline Ki-67 expression.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Participant must have metastatic prostate cancer for which castration (medical or surgical) is no longer effective (castration-resistant).
- Participant must have disease spread to soft tissue that is measurable.
- Participant must have documented evidence of progressive disease by PSA test or imaging.
- Participant must have previously received at least one of the following treatment: abiraterone acetate, apalutamide, darolutamide or enzalutamide.
- Participant must have previously received chemotherapy with docetaxel and cabazitaxel.
- Participant must be willing and amenable to undergo a biopsy of tumor tissue (or able to provide adequate archived tumor tissue sample) and to provide blood for research.
- Participant must have good physical functioning ability and adequate organ function.
- Participant must not have received more than 3 therapy regimens for metastatic castration-resistant prostate cancer (NOTE: GnRHa, first-generation antiandrogens (flutamide, nilutamide, or bicalutamide), diethylstilbestrol (DES) (or other estrogens), corticosteroids, ketoconazole, and bone loss-prevention will not count as systemic therapy regimens.
- Participants must not have previously received abemaciclib or any cyclin-dependent kinase (CDK)4 and/or CDK6 inhibitors.
- Participants must not have serious and/or uncontrolled preexisting medical condition(s) including but not limited to severe renal impairment, severe hepatic impairment, interstitial lung disease (ILD)/pneumonitis, severe dyspnea at rest or requiring oxygen therapy or other serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
- Participants must not have, or suspected to have, brain metastasis.
- Participants must not have untreated spinal cord compression, evidence of spinal metastases with risk of spinal compression or structurally unstable bone lesions suggesting impending fracture.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04408924
|United States, Utah|
|University of Utah - Huntsman Cancer Institute|
|Salt Lake City, Utah, United States, 84112|
|United States, Washington|
|Seattle Cancer Care Alliance|
|Seattle, Washington, United States, 98109|
|Centre Leon Berard|
|Lyon Cedex 08, France, 69373|
|Marseille, France, 13273|
|Hopital Europeen Georges Pompidou|
|Paris, France, 75015|
|Institut Claudius Regaud|
|Toulouse cedex 9, France, 31059|
|Villejuif Cedex, France, 94805|
|Institut Catala d'Oncologia|
|L'Hospitalet de Llobregat, Barcelona, Spain, 08907|
|Corporacion Sanitaria Parc Tauli|
|Sabadell, Barcelona, Spain, 08208|
|Hospital de la Santa Creu i Sant Pau|
|Barcelona, Spain, 08025|
|Hospital Universitari Vall d'Hebron|
|Barcelona, Spain, 08035|
|Hospital General Universitario Gregorio Maranon|
|Madrid, Spain, 28007|
|Hospital Universitario Ramon y Cajal|
|Madrid, Spain, 28034|
|Hospital Universitario 12 de Octubre|
|Madrid, Spain, 28041|
|Study Director:||Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)||Eli Lilly and Company|
Documents provided by Eli Lilly and Company:
|Responsible Party:||Eli Lilly and Company|
|Other Study ID Numbers:||
I3Y-MC-JPCY ( Other Identifier: Eli Lilly and Company )
2020-000290-24 ( EudraCT Number )
|First Posted:||May 29, 2020 Key Record Dates|
|Results First Posted:||May 24, 2023|
|Last Update Posted:||May 24, 2023|
|Last Verified:||April 1, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.|
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
|Time Frame:||Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.|
|Access Criteria:||A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male
Male Urogenital Diseases